Thursday, February 28, 2019 11:35:43 AM
Pro Soccer Players Show Higher ALS Risk
Incidence is rare but more frequent than expected, especially in young players
by Judy George, Contributing Writer, MedPage Today
February 27, 2019
PHILADELPHIA -- Professional soccer players appeared nearly twice as likely to develop amyotrophic lateral sclerosis (ALS) as people in the general population, researchers in Italy suggested.
While the overall likelihood of developing ALS was low, the incidence was 1.9 times higher for Italian professional soccer players than the general population, reported Ettore Beghi, MD, of the Mario Negri Institute for Pharmacological Research in Milan, and colleagues, in an early-release abstract from the American Academy of Neurology annual meeting to be held here in May.
Pro players also developed ALS about 20 years earlier than the general population, they added.
There have been several deaths among Italian professional soccer players from ALS, which prompted this research, Beghi noted. "The disease may result at an earlier age as a result of a genetic predisposition combined to environmental factors, as yet ill-defined -- among them, multiple traumatic events," he told MedPage Today.
Professional soccer is not the only contact sport linked to ALS: in the U.S., increasing numbers of National Football League players have been diagnosed with the disease. Previous studies have shown links between repeated head trauma and ALS, although mechanisms are unknown. An association between exercise and ALS has also been proposed, the researchers noted, but results are conflicting. Links between ALS and use of non-steroidal anti-inflammatory agents and dietary supplements, including branched chain amino acids, also have been suggested.
In this study, Beghi and colleagues looked at all professional soccer players who practiced from 1959 to 2000 in the archives of Panini, a major publisher of Italian football trading cards. They followed each player since the year of start of professional activity, noting demographic and career data, and used news reports to determine which players developed ALS. Using a well-defined Italian population as reference, they calculated the number of cases/100,000 person-years that were expected in the cohort
Overall, 33 professional soccer players developed ALS. Based on the reference population, the number of expected cases in the cohort was 17.6.
The median ALS diagnosis age among soccer players was 43.3 years; a median ALS onset age of 62.5 years in the general population. The standardized incidence ratio was 1.9 (95% CI 1.3-2.6) in the entire sample and 4.7 (95% CI 2.7-7.5) in those under age 45 at diagnosis.
"The study is well designed and executed by a world class team of investigators," observed Robert Miller MD, of the Forbes Norris ALS Research and Treatment Center at California Pacific Medical Center in San Francisco, who was not involved with the analysis.
"The findings are likely correct and should be taken seriously that ALS is two- to five-fold increased in professional soccer players, and probably also in professional football players," he told MedPage Today. "Although this finding appears dramatic, the vast majority of patients with ALS have no history of playing professional contact sports or repeated head injuries."
Head injury is a likely factor "as brain injury is definitely not good for the brain," Miller added, but "the fundamental causes of ALS are still elusive."
The study looked at professional soccer players only, not amateur players, and had few details about ALS diagnosis, Beghi noted.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM

